{"name":"VelaVigo Bio Inc","slug":"velavigo-bio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOWi1mY3E1LXBUaC1XMURMYl9uOWg3dFRtZjJDWDlhZXIzbFpaS1FETjdETHlXdW9mbEd0SlpNb0ViN2M1LUdRbzdCSWRkYkhiYzB4VjBDbnp5ZlZZTElMcUNSMG12Sk5RMEFmTGRKelVRNUttQmZnSU5xaXE4Q1RvalZVRzNnQQ?oc=5","date":"2025-10-28","type":"pipeline","source":"labiotech.eu","summary":"10 biotech companies in China you should know about - labiotech.eu","headline":"10 biotech companies in China you should know about","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQOEdtTV9FSTJpbko0VDFFUXhsazZtanVxTDQwenNTLWtnR1JOT2pWZHZPcDA0bFBCMzB4M1I5eVlXbFdpekxDZGFxWHhXa2tSUHhuYmFrUk9wRVBtSkdfYmxjLUtkSFNlUWozeDRncjhDMDl5RWtlV2J4ZDVBdUhfSWxzQVNPWXIxM1pObHAzWGRuNnlIUF9vRnJMd0hqYWc?oc=5","date":"2025-09-17","type":"pipeline","source":"BioPharma Dive","summary":"Ollin debuts with $100M and plans to challenge top-selling eye drugs - BioPharma Dive","headline":"Ollin debuts with $100M and plans to challenge top-selling eye drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPLWVRMjU1cHg5S0dfSnNqRUFWNngxd3lPVGpvaW41YzFQWVlrbDlWamxpQm51SG9hZU9BTVBiOWl3TWI3VjAtaFFyVGVWdGNZdmhhV0g1RFRmc0hKUDJrVUY2Sl83cWJ1eDJhd25Bdk5yQ01NbWd1cEF1RWRYZ0JBYnJjY2hqV2ViaE1lMGNCazZVcXNGSlRIRDYtb3I0RXM4V05yNzU5SklSdUxNWWh6ZVRRVXQwaTNJbWtv?oc=5","date":"2025-04-25","type":"trial","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Enhertu's first-line win; Akeso bispecific's positive readout; Regeneron, Fujifilm's $3B deal - Fierce Pharma","headline":"Fierce Pharma Asia—Enhertu's first-line win; Akeso bispecific's positive readout; Regeneron, Fujifilm's $3B deal","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE9Zc2phRWx0NUlFdDZLV2NUeW0wZFliR0d1MU01S3pPSmRyczdKTW1rcGdMWmF4RzRQb2RldmYzSFl6NmFNM2xZc24xMGw1TjA3SXc?oc=5","date":"2025-04-22","type":"pipeline","source":"The Pharma Letter","summary":"VelaVigo - The Pharma Letter","headline":"VelaVigo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1QczBXLVhxWjBoby1VWGdPN1JmQ3dQaEQ2OHIzeTdCSE95SnVkMnpqWnBLSVduc1k5dU5CeTRpVUx4VHhRcWVKUEhJczNwUHJQWGFRQlJKWWh6aDNFYWVIaHladzViV1owZEhFN1R1N0dPZ1Y2QVlDbkNvMTJsQkU?oc=5","date":"2025-04-21","type":"deal","source":"The Pharma Letter","summary":"VelaVigo bags second US out-licensing deal - The Pharma Letter","headline":"VelaVigo bags second US out-licensing deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxPZFBIVjlqRFJYekVoYWpNZ3VDQmhfSy1sYTlibk5sY0U2bHJiRXRzNUoyMkdiNDRPM01yWHFrY1p1dU1mcW5qQlVqX05iaGRZanFkbkJmbXRfeHRKRWpKZnltUktYZnVWT2NneHUtcVNVaW5PTXNyU0tjT1RTaEo1UmdlV25ZSndXN1R5MDhxMTVzS2xJMEstcFJYNWhiYTRyQ0xJaDFzTnFveXFQLXVzNWJHQjJMa05Mbmlvb0tkSjFGWldDWGRoajZHLUxtZnN1NjBlb09qTXhkS3NPdGhaeGZHMkJzZ3Nrbml5WnVOakI?oc=5","date":"2025-04-18","type":"deal","source":"BioPharma APAC","summary":"VelaVigo Bio Signs $440M Global Licensing Deal with Ollin Biosciences for First-in-Class Bispecific Antibody VBS-102 - BioPharma APAC","headline":"VelaVigo Bio Signs $440M Global Licensing Deal with Ollin Biosciences for First-in-Class Bispecific Antibody VBS-102","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPYi1MRU9ES1RRMjhsN2JmQlJXWUhQZmVnd0NUSmVEMUdlMEF1UFB6VEhnaFI1SXJycnRZVG9YY1dVMGRMeUJ5SUowdk1JZXlfN2VaWmdsRmgzRVRGQUQxVFlzTVdUaWFfd0ZSWTZ4V3lrR0hCbm1LdVV2YXJaQzVKR3AwU2Q5VERRTk9HQjE1UUh3cjltQTNvOUVfOA?oc=5","date":"2025-04-18","type":"deal","source":"Fierce Biotech","summary":"Stealth biotech bags rights to VelaVigo bispecific in $440M deal - Fierce Biotech","headline":"Stealth biotech bags rights to VelaVigo bispecific in $440M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE41WUcwd3UxSVZrNE52SzMwaDYwX1J2TmFZNmx3R0hSWUM3b0laUklCak1CX042c2JVZzc3RVgwbzdrR1ZzUTB5SVFjQ0ZzQnlZNmNDY01vR09yLVZXRmUtSk1LQXRVdHZ0c2JkXzNfNHcxWHY0?oc=5","date":"2025-04-12","type":"deal","source":"labiotech.eu","summary":"Top biotech deals of April 2025 - labiotech.eu","headline":"Top biotech deals of April 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1LbkZVQ1NuR2h3a2U3WFdnU1pWVjd0S2ljeVp3bjRoR1prVjJYLThuNUd1V0xFN3ZlTm16REJOa1BfLXdIUzRCUjY3VWhGZEdEVTkxZk8zdDVEQWRwTmVJ?oc=5","date":"2025-04-04","type":"deal","source":"Nature","summary":"Analysis of China-to-West pharmaceutical licensing deals in 2024 - Nature","headline":"Analysis of China-to-West pharmaceutical licensing deals in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOQW9sWHhfN19pZnE2QzFsbWhDMUUxX2hfWFpwbzJ1d245c0xZa2QxS1hBSWx2N2VJalRycWEwQml1Q1ZlT1pZaVVUZ2xZdXVTZDlQWmxYYVhwSW1KY0Ruc0t0c0lHU2ZkOXhSSy1ST3B1VlByb2ttY1RMY0ZKWDNiV2JsWjA?oc=5","date":"2021-12-18","type":"pipeline","source":"BioCentury","summary":"Tong Zhang joins Jing Li at VelaVigo - BioCentury","headline":"Tong Zhang joins Jing Li at VelaVigo","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}